BioCentury | Jun 9, 2014
Emerging Company Profile

Glactone: ProSTATe stopper

...STAT3 by reducing JAK2 levels. Companies and Institutions Mentioned AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Glactone Pharma AB...
...Sweden Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Otsuka Pharmaceutical Co. Ltd ., Tokyo, Japan Sidebars Glactone Pharma AB...
BioCentury | May 29, 2014
Distillery Therapeutics

Indication: Cancer

...and in combination with other therapies for castration-resistant prostate cancer caused by excessive STAT3 activity. Glactone Pharma AB...
...trials for solid tumors. SciBX 7(21); doi:10.1038/scibx.2014.613 Published online May 29, 2014 Patented; licensed to Glactone Pharma...
Items per page:
1 - 2 of 2
BioCentury | Jun 9, 2014
Emerging Company Profile

Glactone: ProSTATe stopper

...STAT3 by reducing JAK2 levels. Companies and Institutions Mentioned AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Glactone Pharma AB...
...Sweden Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Otsuka Pharmaceutical Co. Ltd ., Tokyo, Japan Sidebars Glactone Pharma AB...
BioCentury | May 29, 2014
Distillery Therapeutics

Indication: Cancer

...and in combination with other therapies for castration-resistant prostate cancer caused by excessive STAT3 activity. Glactone Pharma AB...
...trials for solid tumors. SciBX 7(21); doi:10.1038/scibx.2014.613 Published online May 29, 2014 Patented; licensed to Glactone Pharma...
Items per page:
1 - 2 of 2